ORIGINAL RESEARCH article
Front. Immunol.
Sec. Autoimmune and Autoinflammatory Disorders: Autoinflammatory Disorders
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1619490
This article is part of the Research TopicCommunity Series in Towards Precision Medicine for Immune-Mediated Disorders: Advances in Using Big Data and Artificial Intelligence to Understand Heterogeneity in Inflammatory Responses, Volume IIIView all 4 articles
Exploring Immune-Inflammation Markers in Psoriasis Prediction Using Advanced Machine Learning Algorithms
Provisionally accepted- Chengdu Third People's Hospital, Chengdu, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Psoriasis is a chronic immune-mediated inflammatory skin disorder characterized by multifactorial pathogenesis. Recent studies have extensively highlighted the strong associations between psoriasis and various inflammatory markers, which are considered novel predictive tools for evaluating systemic inflammation.Methods: Cross-sectional data from the NHANES were analyzed in this study. To assess model performance and generalizability, the dataset was randomly divided into 70% for training and 30% for validation. To address class imbalance in the training data, a hybrid resampling technique (SMOTEENN) was applied. Subsequently, nine classification algorithms were developed using the processed training set, including random forest, neural networks, XGBoost, k-nearest neighbors, gradient boosting, logistic regression, naïve Bayes, AdaBoost, and SVMs. The final gradient boosting was implemented via the gbm package in R, with hyperparameters selected from the default tuning grid of the caret framework. Inflammatory biomarkers with the highest classification utility were identified based on the predictions of the best-performing model.Results: A total of 22,908 participants were included in the final analysis. Gradient boosting (AUC: 0.629, 95% CI: 0.588-0.669) demonstrated the highest performance, followed closely by logistic regression (AUC: 0.627, 95% CI: 0.588-0.666). Among all the inflammatory markers, MLR exhibited the best classification performance, with an AUC value of 0.662 (95% CI: 0.640-0.683), followed by NLMR, with an AUC value of 0.661 (95% CI: 0.640-0.683). Other markers, including the NLR, dNLR, SII, SIRI, and PLR, had AUC values ranging from 0.658 to 0.661. The MLR had the highest relative importance score, demonstrating its critical role in the model's predictive performance for psoriasis classification. The NLR ranked second, followed by the SII and SIRI, which had moderate contributions, whereas the PLR contributed the least.Conclusions: Among all the tested algorithms, the gradient boosting model achieved the best performance. Not only does it achieve the highest predictive accuracy, but it also excels in classification efficacy and feature importance analysis, highlighting key inflammatory markers such as the MLR, SII, and NLR. These markers are significant as reliable indicators for evaluating systemic inflammation and predicting the development of psoriasis, emphasizing their potential clinical applications.
Keywords: Psoriasis, national Health and Nutrition Examination Survey (NHANES), machine learning algorithms, Monocyte-to-lymphocyte ratio (MLR), Neutrophil-to-monocyte ratio (NLMR)
Received: 28 Apr 2025; Accepted: 15 Jul 2025.
Copyright: © 2025 Yang, He, Tang, Qin and Zheng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Xiao Qin, Chengdu Third People's Hospital, Chengdu, China
Yan Zheng, Chengdu Third People's Hospital, Chengdu, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.